Vaccines
Vaccines induce antigen-specific immunity to prevent or reduce disease and transmission from pathogens and biological agents. MTEC accelerates antigen design, adjuvant optimization, thermostable formulations, and rapid manufacturing to deliver single-dose, mucosal, and field-deployable vaccine platforms that sustain force readiness in austere and prolonged-care settings.
Technical Challenges
High pathogen diversity, antigenic drift, and emerging zoonoses that require rapid antigen design and breadth of protection.
Cold-chain dependence and formulation instability limiting vaccine use in austere or prolonged-field-care environments.
Need for rapid, scalable manufacturing and platform standardization to respond to novel biological threats.
Limited single-dose and mucosal vaccine options that confer fast-onset, durable protection suitable for operational timelines.
Administration constraints in the field: needle-free, low-training delivery and minimized medical logistics.
Emerging Opportunities
Thermostable, lyophilized or ambient-stable formulations for long-duration storage without cold chain.
Plug-and-play vaccine platforms (e.g., mRNA/viral vectors) validated for rapid pivot to novel threats and accelerated scale-up.
Single-dose or rapid-immune-onset vaccines and adjuvants optimized for immunocompromised or stressed Warfighters.
Field-deployable delivery solutions (microneedle patches, mucosal sprays) that reduce trained-provider dependency.
Integrated regulatory and clinical-pathway models for expedited DoD-focused approvals and dual-use transition.
Current and Emerging Technologies in Vaccines
mRNA and self-amplifying RNA platforms
Rapid antigen encoding, adaptable for emerging pathogens; enables fast design-to-clinic timelines with potential for single-dose immunogenicity when combined with optimized delivery and adjuvants.
Viral vector vaccines
Non-replicating and replicating vectors provide robust cellular and humoral responses; useful for biodefense antigens and situations requiring durable protection.
Protein subunit and nanoparticle vaccines
Engineered antigens and nanoparticle display platforms enhance immunogenicity and breadth while enabling established cold-chain-reduced formulations.
Advanced adjuvants and immune modulators
New adjuvant systems accelerate onset of protection, bias durable cellular or mucosal immunity, and reduce antigen dose — critical for operational constraints.
Thermostable formulations & lyophilization
Formulation science, excipients, and drying technologies preserve potency at ambient temperatures to eliminate or reduce cold-chain burdens in remote or prolonged operations.
Mucosal and needle-free delivery
Intranasal sprays, oral platforms, and dissolvable microneedle patches enable rapid, low-skill administration with potential to block transmission at entry portals.
Rapid manufacturing and point-of-care production
Modular, GMP-ready manufacturing units and platform standardization shorten ramp-up time for surge production in response to outbreaks or biodefense events.
Importance to Military Medicine
Force readiness and outbreak prevention
Vaccination prevents infectious disease-related attrition, preserves unit cohesion, and sustains mission capability during deployments and humanitarian responses.
Prolonged and austere care applicability
Thermostable, single-dose, and needle-free vaccines reduce logistical footprints and are tailored for delayed evacuation or prolonged-field-care scenarios.
Biodefense and rapid response
Validated platforms and rapid manufacturing underpin preparedness for biological threats and enable timely countermeasure deployment to protect personnel and civilians.
Reduced morbidity to preserve operational capability
Effective vaccines limit disease severity, hospitalization, and long-term sequelae that would otherwise degrade sustained combat and support operations.
Alignment with the MTEC Mission
Accelerates DoD-prioritized medical technologies from concept to field use, emphasizing rapid translation and operational relevance.
Supports infectious disease and biodefense portfolios by funding platform validation, clinical studies, and manufacturing scale-up aligned with military requirements.
Drives dual-use impact—prioritizing Warfighter protection while enabling civilian public-health benefits and commercial transition.
Dual-Use (Military + Civilian) Applications
Civilian pandemic response: platform technologies and thermostable vaccines reduce global morbidity and enable faster public-health deployments.
Commercial vaccine innovation: industry adoption of military-validated platforms accelerates manufacturing efficiencies and supply-chain resilience.
Global health and humanitarian use: needle-free and ambient-stable products expand reach in low-resource settings.
Surge capacity and biodefense: point-of-care manufacturing and modular platforms support rapid countermeasure scaling for civilian and military needs.
Explore MTEC Members with Vaccines Capabilities
MTEC members bring capabilities across antigen discovery, platform engineering (mRNA, vectors, protein), adjuvant science, GMP manufacture, and clinical trial networks—enabling end-to-end vaccine development tailored to military constraints.
Explore member profiles to find partners with rapid-prototyping labs, stovepipe-busting regulatory experience, and deployment-oriented product design to accelerate vaccinelife-cycle transition to the field and civilian use.
138 Members with Vaccines capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
The Precision Vaccines Program (PVP), based in the Department of Pediatrics at Boston Children’s Hospital, is an academic research initiative dedicated to discovering and developing next-generation vaccines tailored to vulnerable populations. PVP conducts both basic and translational research to create novel vaccines and therapeutics for diseases that disproportionately affect infants, older adults, and immunocompromised individuals. The program brings together experts in vaccinology, clinical trials, immunology, molecular biology, data management, biostatistics, bioinformatics, and systems biology, fostering international collaboration among academia, government, and industry to advance precision medicine in vaccinology.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
BioPharma Connections is an independent, woman-owned consulting firm founded in San Francisco in 2007, providing strategic business development, technical operations, regulatory, product development, and commercialization support to the life sciences industry. Serving pharmaceutical, biotechnology, medical device, and diagnostic companies globally, the firm specializes in facilitating connections between organizations, service providers, CROs, CDMOs, and investors—guiding clients from concept to commercialization, with deep expertise in regulatory compliance, emerging technologies, and diverse therapeutic areas.
The Institute for Integrative & Innovative Research (I³R) at the University of Arkansas is dedicated to pioneering solutions to wicked problems and societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I³R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Revolution Biomanufacturing Inc. (RBIx) is expanding beyond traditional CDMO Process/Analytical Development and Manufacturing services to pioneer distributed molecular manufacturing. A new class of digital biomanufacturing that enables the autonomous design, manufacture, quality verification, and deployment of Nucleic Acid therapeutics and molecular diagnostics at the point of need. By integrating AI-driven sequence optimization, enzymatic nucleic acid synthesis, Nanoparticle design and manufacturing (LNP & EV), closed-loop quality control, and field-deployable manufacturing platforms, RBIx is creating adaptive biological infrastructure capable of responding to emerging diseases, national security threats, and personalized medicine with unprecedented speed and flexibility.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Sunflower Therapeutics is a women-owned and led biotechnology public benefit corporation founded in 2018, dedicated to democratizing access to protein manufacturing worldwide. The company develops next-generation, automated, and fully-integrated protein manufacturing solutions that simplify the process from discovery to full-scale biomanufacturing. Their mission is to make high-quality, cost-effective therapeutics, vaccines, and protein-based products accessible globally, especially in low- and middle-income countries, by leveraging innovative technologies, sustainable practices, and intuitive equipment. Sunflower’s vision is to transform the global health landscape by enabling more medicines and protein products to reach patients and consumers everywhere. Their core technologies include efficient microbial hosts, data-driven process development, and modular manufacturing facilities, supporting agile, rapid, and cost-effective production cycles for a wide range of protein-based products.

Safi Biotherapeutics
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness
Applied Cognition is developing non-invasive glymphatic monitoring and recovery technologies to enhance warfighter cognitive readiness, resilience, and sleep recovery.
Moberg Analytics
Moberg Analytics – Advanced Brain Monitoring & Critical Care Informatic
Moberg’s platform unifies brain monitoring data for faster, precise treatment of severe brain injuries in military and civilian care.
University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.